



SHAREABLE PDF

# Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective

David M.G. Halpin<sup>1,2</sup>, Dave Singh<sup>2,3</sup> and Ruth M. Hadfield<sup>2,4</sup>

**Affiliations:** <sup>1</sup>University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK. <sup>2</sup>Global Initiative for Chronic Obstructive Lung Disease (GOLD). <sup>3</sup>University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. <sup>4</sup>Macquarie University, Sydney, Australia.

**Correspondence:** David M.G. Halpin, University of Exeter Medical School, Smeall Building, St Luke's Campus, Magdalen Road, Exeter EX1 2LU, UK. E-mail: d.halpin@nhs.net

 @ERSpublications

**There is no evidence on benefits or harms of inhaled steroids in COVID-19. It is essential that epidemiological studies of COVID-19 include detailed information on comorbidities and prior medication to help answer this question.** <https://bit.ly/2XVwIsa>

**Cite this article as:** Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. *Eur Respir J* 2020; 55: 2001009 [<https://doi.org/10.1183/13993003.01009-2020>].

This single-page version can be shared freely online.

The current coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, raises important questions as to whether pre-morbid use or continued administration of inhaled corticosteroids (ICS) affects the outcomes of acute respiratory infections due to coronavirus. Many physicians are concerned about whether individuals positive for SARS-CoV-2 and taking ICS should continue them or stop them, given that ICS are often regarded as immunosuppressive. A number of key questions arise. Are people with asthma or COPD at increased risk of developing COVID-19? Do ICS modify this risk, either increasing or decreasing it? Do ICS influence the clinical course of COVID-19? (figure 1). Whether ICS modify the risk of developing COVID-19 or the clinical course of COVID-19 in people who do not have lung disease should also be considered (figure 1).